title: Denosumab for the treatment of bisphosphonate resistant hypercalcemia in a hemodialysis patient.
abstract: The acronym of malignancy, iatrogenic, intoxication and immobilization, sarcoidosis, hyperparathyroidism and hyperthyroidism, milk-alkali syndrome, and paget is very helpful in diagnosing hypercalcemia. We report on a 94-year-old patient with history of end-stage renal failure secondary to benign nephroangiosclerosis, who was on maintenance hemodialysis during dialysis, his blood chemistry revealed mild hypercalcemia (2.66 mmol/L) with normal level of intact primary hyperparathyroidism (32.37 ng/mL) mandating the discontinuation of Vitamin D[3]. In view of persisting hypercalcemia, denosumab 60 mg/mL was administrated subcutaneously. The serum calcium level showed a decrease and stabilized at near upper limit (2.57 mmol/L). Three weeks later, the serum calcium remained mildly elevated fluctuating between 2.66 and 2.80 mmol/L.
authors.affiliation: Department of Nephrology and Dialysis, Hospital Louis Jaillon, Saint-Claude, France.
authors.forename: Omar
authors.initials: O
authors.lastname: Dahmani
authors.affiliation: Secondary Care, Hospital Louis Jaillon, Saint-Claude, France.
authors.forename: Christine
authors.initials: C
authors.lastname: Sophoclis
authors.affiliation: Secondary Care, Hospital Louis Jaillon, Saint-Claude, France.
authors.forename: Malika
authors.initials: M
authors.lastname: Kebir
authors.affiliation: Department of Nephrology and Dialysis, Hospital Louis Jaillon, Saint-Claude, France.
authors.forename: Djemai
authors.initials: D
authors.lastname: Bouguern
authors.affiliation: Secondary Care, Hospital Louis Jaillon, Saint-Claude, France.
authors.forename: Aboubacry
authors.initials: A
authors.lastname: Sakho
authors.affiliation: Department of Nephrology and Dialysis, Hospital Louis Jaillon, Saint-Claude, France.
authors.forename: Pascale
authors.initials: P
authors.lastname: Demarchi
mesh_terms: D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002118:Calcium / Q000097:blood*; D000069448:Denosumab / Q000627:therapeutic use*; D004164:Diphosphonates / Q000627:therapeutic use*; D004351:Drug Resistance; D057915:Drug Substitution; D006801:Humans; D006934:Hypercalcemia / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D008297:Male; D006435:Renal Dialysis / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000069448:Denosumab; D002118:Calcium